MBRX vs. MNPR, MTEM, AEZS, ELAB, AKTX, GRTX, GHSI, IMNN, ERNA, and MIRA
Should you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include Monopar Therapeutics (MNPR), Molecular Templates (MTEM), Aeterna Zentaris (AEZS), Elevai Labs (ELAB), Akari Therapeutics (AKTX), Galera Therapeutics (GRTX), Guardion Health Sciences (GHSI), Imunon (IMNN), Eterna Therapeutics (ERNA), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical preparations" industry.
Monopar Therapeutics (NASDAQ:MNPR) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership, community ranking and analyst recommendations.
1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are owned by institutional investors. 41.6% of Monopar Therapeutics shares are owned by insiders. Comparatively, 6.7% of Moleculin Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Moleculin Biotech had 2 more articles in the media than Monopar Therapeutics. MarketBeat recorded 4 mentions for Moleculin Biotech and 2 mentions for Monopar Therapeutics. Moleculin Biotech's average media sentiment score of 0.00 equaled Monopar Therapeutics'average media sentiment score.
Moleculin Biotech received 189 more outperform votes than Monopar Therapeutics when rated by MarketBeat users. However, 70.37% of users gave Monopar Therapeutics an outperform vote while only 53.29% of users gave Moleculin Biotech an outperform vote.
Monopar Therapeutics presently has a consensus price target of $2.00, indicating a potential upside of 143.90%. Moleculin Biotech has a consensus price target of $35.00, indicating a potential upside of 594.44%. Given Monopar Therapeutics' higher possible upside, analysts clearly believe Moleculin Biotech is more favorable than Monopar Therapeutics.
Monopar Therapeutics has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500.
Monopar Therapeutics is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.
Monopar Therapeutics' return on equity of -80.91% beat Moleculin Biotech's return on equity.
Summary
Moleculin Biotech beats Monopar Therapeutics on 9 of the 13 factors compared between the two stocks.
Get Moleculin Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Moleculin Biotech Competitors List
Related Companies and Tools
